Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Psilocybin studies
Explore psilocybin studies by research question and study design. Compare human trials, observational reports, reviews and preprints with source-linked evidence.
Free access · No subscription for research tools or data exports
Understand the different kinds of psilocybin study
Psilocybin studies include randomized human trials, observational reports, studies in healthy volunteers, animal and laboratory experiments, and registered trial plans. They answer different questions. A registered study establishes a research plan; an observational improvement does not by itself establish causation. A positive randomized endpoint still needs interpretation alongside the comparator, follow-up and adverse events.
Human clinical studies
Compare the selected depression and alcohol-use studies by population, treatment setting, primary endpoint and follow-up. Their findings concern the supervised interventions studied, not unrestricted use.
Compare selected findings and limitationsCurrent and recruiting studies
Use exact registry recruitment status to locate ongoing psilocybin clinical studies. Start and completion dates are registry facts; they do not establish efficacy, publication or personal eligibility.
Recruiting psilocybin studiesLaboratory and mechanism studies
Mechanistic and animal experiments can help formulate hypotheses. Their endpoints and populations differ from clinical outcomes, so they should not be presented as direct evidence of treatment effectiveness.
Explore mechanism-related literatureReviews, protocols and preprints
Reviews synthesise existing work, protocols describe planned methods, and preprints have not been peer reviewed. Preserve these distinctions when building an evidence set.
Research reading checklistBrowse indexed psilocybin studies
4859 matching records; first 20 shown. Derived labels aid screening and need verification against the methods. Coverage is broad but not exhaustive.
Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurementPérez Rosal Sergio R., Faber Sonya C. · 2026-12-01 · Psychedelics · PublishedMindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery modelAlbertyn Christopher P., Richard Jérémie, Shore Ron, Carlson Linda E. · 2026-12-01 · Psychedelics · PublishedPupil-DLC: An open-source deep learning pipeline for scalable, marker-less tracking of pupil dynamics across conscious and unconscious states.Seyfourian P, Marks LC, Claar LD, Nahas Y, Keating M, Koch C, Rembado I · 2026-11-01 · Journal of neuroscience methods · PublishedChanges in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionKelly Carlton M., Fradet Mathieu, Bostian Catherine M., Donnelly Anna, Ellis Sara, Ostacher Michael, Aaronson Scott, Suppes Trisha · 2026-11-01 · Journal of Affective Disorders · PublishedPsychedelics restructure information in the human brainBlackburne, G.; Liardi, A.; Mallaroni, P.; McAlpine, R.; Carhart-Harris, R.; Timmermann, C.; Muthukumaraswamy, S. D.; Skipper, J. I.; Mediano, P. A. M. · 2026-10-08 · bioRxiv · PREPRINT (not peer reviewed)Preparing the body for psilocybin therapy: receptive and generative interoception in cancer patientsBack Anthony L., Price Cynthia J., McGregor Bonnie A., Markell Andrew · 2026-10-08 · Frontiers in Psychiatry · PublishedPilot Study on the Effects of Psilocybin on Belief Updating and Insight FormationBrown University · 2026-10-08 · ClinicalTrials.gov · CLINICAL TRIALMusic for psilocybin therapy and the temporal arc of psychedelic experienceGómez-Cañón Juan Sebastián, Leininger Carly, Mayall Danielle, Dougherty Robert F., Bowling Daniel L. · 2026-10-08 · Scientific Reports · PublishedNeuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseNational Institute on Aging (NIA) · 2026-10-08 · ClinicalTrials.gov · CLINICAL TRIALAcute psilocybin or ethocybin leads to a sustained increase in Pavlovian aversion memory in male miceHogg D, Romanos J, Albiez J, Hofer C, Wicki S, Argunşah A, Sigrist H, Thomann J, Luethi D, Vollenweider F, Pryce C. · 2026-10-07 · Frontiers in pharmacology · PublishedPsilocybin use, mental health treatment utilization, and unmet treatment need among US individuals with depression.Eun AC, Yang KH, Palamar JJ · 2026-10-06 · Psychological medicine · PublishedWhat Is Psilocybin?Walter Kristin L. · 2026-10-06 · JAMA · PublishedPsilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label TrialUnity Health Toronto · 2026-10-06 · ClinicalTrials.gov · CLINICAL TRIALA Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderCOMPASS Pathways · 2026-10-06 · ClinicalTrials.gov · CLINICAL TRIALPsilocybin-Assisted Therapy in Depressive Disorders: Clinical Governance, Safety, and Translational ChallengesSzilvia Salima Bartha Msc In Business Administration · 2026-10-05 · Venue unknown · PublishedCaution before canonisation: a clinical and implementation science perspective on psychedelicsAndreas Paris, Foteïni Thoma, Aikaterini Velentza, Panagiota Pavlopoulou, Giorgos Metaxas · 2026-10-05 · Frontiers in Psychiatry · PublishedPsychedelics Restructure the Global Workspace of ConsciousnessYousefi, P.; Shinozuka, K.; Vizeli, P.; Holze, F.; Becker, A. M.; Muller, F.; Liechti, M. E.; Hasler, G.; Rodriguez, C. I.; Luppi, A.; Mediano, P. A. M. · 2026-10-05 · bioRxiv · PREPRINT (not peer reviewed)Therapists’ Perspectives on the Psychotherapeutic Support in Psilocybin Treatment for Major Depressive Disorder: Insights from a Randomized Controlled TrialKjellgren A, Lundberg J, Yngwe H, Ekman CJ, Tiger M, Ljunglöf T, Stridh F, Beckman M. · 2026-10-05 · Research Square · PREPRINT (not peer reviewed)An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder.Tiwari, P.; Nayak, S. M.; Sepeda, N. D.; Ehrenkranz, R.; Levine, M. A.; Rohde, J. S.; Miller, E.; Beritela, C. M.; Scott, J. V.; Nestadt, G.; Barrett, F. S.; Yaden, D. B. · 2026-10-05 · medRxiv · PREPRINT (not peer reviewed)Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive ImpairmentCentre for Addiction and Mental Health · 2026-10-05 · ClinicalTrials.gov · CLINICAL TRIAL
Research questions with source-linked context
Psilocybin studies for depressionPsilocybin and alcohol-use studiesTopics, selected reports and outcome measuresPublication trends and denominators
Publication dates, study dates and indexing dates may differ. Clinical trial registrations describe planned methods, while primary reports describe findings. Read the editorial policy for source tracking, corrections and classification limits.